Vectura News

Discover more about our company, science, innovation and people with the latest headlines from Vectura.

Displaying 57 of 57

Vectura and Inspira Pharmaceuticals Sign Agreement to Develop Potential Inhaled Treatment for COVID-19

Published06/05/2021

Read more
Showcasing our scientific expertise at Respiratory Drug Delivery Congress (RDD) 4th-7th May, 2021

Published28/04/2021

Read more
Vectura highlights update made by Hikma on launch of generic Advair Diskus®

Published21/04/2021

Read more
“Strategies for rapid progression of inhaled products” at Formulation & Delivery Europe Congress: Online

Published15/04/2021

Read more
Will Downie named in The Medicine Maker’s Power List for 2021

Published15/04/2021

Read more
Vectura Group publishes 2020 preliminary results

Published18/03/2021

Read more
Vectura Expands Dry Powder Inhaler Development and Manufacturing Capabilities at its Facility in Chippenham, U.K.

Published05/03/2021

Read more
Vectura Virtual Audits

Published26/02/2021

Read more
Pre-close trading update confirms 2020 trading ahead of expectations

Published12/01/2021

Read more
Vectura Group appoints Jeanne Hecht and Jeanne Thoma to its Board of Directors

Published30/12/2020

Read more
Vectura provides update on GSK litigation

Published29/12/2020

Read more
Vectura earns $11m milestone as Hikma receives US FDA approval for generic Advair Diskus®

Published17/12/2020

Read more
Vectura Expands Capabilities to Handle and Develop Highly Potent Inhaled Drugs at its Facility in Chippenham, U.K.

Published14/12/2020

Read more
Vectura signs agreement with Kinaset Therapeutics Inc. to support the development of VR588 to treat asthma

Published30/11/2020

Read more
Vectura provides update on GSK litigation

Published19/11/2020

Read more
Will Downie’s podcast: “There’s a patient at the end of every piece of work we do…”

Published08/10/2020

Read more
Vectura shortlisted for ’Excellence in Pharma: Contract Services and Outsourcing’

Published24/09/2020

Read more
Status update on VR315 (US)

Published22/09/2020

Read more
2020 Interim Results

Published15/09/2020

Read more
Vectura partners with Monash University to support development of inhaled oxytocin to prevent postpartum haemorrhage

Published14/09/2020

Read more
Notice of Interim Results

Published06/08/2020

Read more
QVM149 receives regulatory approval in Europe and Japan

Published07/07/2020

Read more
Live Webcast 24th June: Dry Powder Inhalers – Key Considerations for Combination Product Development

Published17/06/2020

Read more
Vectura signs agreement with Aerami Therapeutics Inc.

Published08/06/2020

Read more
Vectura expands business development team with three global appointments

Published03/06/2020

Read more
Podcast: Breathing new life into existing drugs

Published28/05/2020

Read more
Share buyback and AGM trading update

Published27/05/2020

Read more
Podcast: Vectura presents latest science at Digital RDD 2020

Published17/04/2020

Read more
Vectura’s response to the COVID-19 outbreak

Published19/03/2020

Read more
Vectura publishes 2019 preliminary results

Published17/03/2020

Read more
Vectura appoints Mark Bridgewater as Chief Commercial Officer

Published09/03/2020

Read more
Sharon Johnson appointed Executive Vice President for Delivery Management

Published10/02/2020

Read more
Pre-close trading update confirms 2019 trading in-line with expectations

Published13/01/2020

Read more
Meet our inhalation experts at Drug Delivery to the Lungs (DDL) 2019

Published03/12/2019

Read more
VR315US: Hikma submits response to FDA

Published27/11/2019

Read more
Vectura to present latest science at Drug Delivery to the Lungs (DDL) 2019

Published22/10/2019

Read more
Vectura Group appoints New Chief Executive Officer

Published15/10/2019

Read more
Results of the General Meeting held on 10th October 2019

Published10/10/2019

Read more
Vectura provides update on GSK litigation

Published13/09/2019

Read more
Vectura delivers strong H1 2019 financial performance

Published10/09/2019

Read more
Proposed increased capital return to shareholders of approx. £60m

Published09/09/2019

Read more
Proposed £50 million capital return and trading update

Published17/07/2019

Read more
Vectura Group Plc announces leadership changes

Published10/06/2019

Read more
QVM149 submission means early $2.5m payment for Vectura

Published24/05/2019

Read more
Vectura data to be shared at ATS 2019

Published15/05/2019

Read more
Vectura wins US GSK patent litigation and awarded $89.7m in damages by jury

Published26/04/2019

Read more
R&D: Transformation frees up more resources for innovation

Published10/04/2019

Read more
Vectura reports strong 2018 financial and operational performance

Published26/03/2019

Read more
Pre-close trading update confirms good progress against 2018 goals

Published03/01/2019

Read more
Global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio

Published08/11/2018

Read more
Rising to the challenge of developing inhaled generic medicines

Published26/09/2018

Read more
Vectura Group Interim Results for H1 2018

Published11/09/2018

Read more
Fundraising for AsthmaUK

Published06/07/2018

Read more
Bringing nebuliser device and formulation together

Published05/07/2018

Read more
New product creation – from paper to market

Published04/07/2018

Read more
Generic programmes

Published03/07/2018

Read more

Displaying 57 of 57